Letters by company
Precigen, INC.
6 letters discussing PGEN. Everything written about it on this site is on its ticker page.
- Patient Capital Management 3Q25 Portfolio Activity & Attribution Patient Opportunity Equity Strategy added to Delta Air Lines and Norwegian Cruise Line during travel-sector weakness, doubled UnitedHealth after its pullback, and converted Precigen preferreds into common stock after Papzimeos won FDA approval. The strategy argues that Alphabet and Alibaba remain undervalued despite improving fundamentals, while maintaining conviction in turnarounds at Dave & Buster's, QXO and Crocs. 3Q25 PGEN $2.8BBABA $270BCROX $5.5B
- Patient Capital Management 3Q25 Portfolio Recap Patient Opportunity Equity built Precigen through a preferred investment ahead of Papzimeos approval, then converted shares and trimmed the enlarged exposure while backing its HPV and CAR-T pipeline. It added aggressively to UnitedHealth amid insurance-cycle pressures, and redeployed toward Crocs, Mattel, IAC and Biogen as valuations rose. 3Q25 PGEN $2.8BUNH $338B
- Patient Capital Management 2Q26 Portfolio Activity & Attribution Opportunity Equity added Adyen, Global Payments, Genius Sports, Fidelity Wise Origin Bitcoin Fund and QXO preferred securities while exiting IBIT, Noble and Dave & Buster's. The strategy argues that depressed expectations create value in health care, payments, biotech and selected software, while retaining conviction in QXO's building-products consolidation strategy. second quarter of 2026 ADBE $90BADYEN $31BBIIB $33B
- Patient Capital Management 4Q25 Portfolio Activity and Attribution Patient Opportunity Equity added long-dated Biogen calls, initiated Fiserv and Chime, and exited Angi, arguing Biogen's Alzheimer’s franchise and pipeline offer upside while Fiserv can recover following a management reset. It backed Alphabet’s AI monetization, Precigen’s Papziemos launch, Illumina’s sequencing recovery, Coinbase’s platform expansion and Bitcoin’s scarcity. 4Q25 BIIB $33BCHYM $11BCOIN $47B
- Patient Capital Management 4Q24 Portfolio Activity and Attribution Patient Opportunity Equity Strategy added Precigen preferreds and warrants and a Bitcoin fund, while exiting Fiserv, PureTech Health, Travel & Leisure and Western Alliance. The strategy added to healthcare and energy laggards, arguing that Coinbase, SoFi and travel holdings retain structural growth drivers. 4Q24 COIN $47BCROX $5.5BCVS $112B
- Patient Capital Management 3Q24 Portfolio Activity and Attribution Patient Opportunity Equity added QXO and Dave & Buster’s, funded in part by exits from JPMorgan and Everi following its acquisition. The portfolio argues that QXO’s acquisition-led building-products strategy, Kosmos’s approaching cash-flow inflection, and Seadrill’s tightening deepwater-rig market offer idiosyncratic upside beyond macro conditions. 3Q24 BABA $270BET $70BEXPE $31B
